Similar articles

• Mechanisms for pyrrolizidine alkaloid activation and detoxification.

  Buhler DR, Miranda CL, Kedzierski B, Reed RL. Buhler DR, et al. Adv Exp Med Biol. 1991;283:597-603. doi: 10.1007/978-1-4684-5877-0_75. Adv Exp Med Biol. 1991. PMID: 2069028 No abstract available.
• 7-Glutathione-pyrrole and 7-cysteine-pyrrole are potential carcinogenic metabolites of pyrrolizidine alkaloids.

  He X, Xia Q, Fu PP. He X, et al. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017 Apr 3;35(2):69-83. doi: 10.1080/10590501.2017.1298358. Epub 2017 Mar 1. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2017. PMID: 28418776
• Biliary excretion of novel pneumotoxic metabolites of the pyrrolizidine alkaloid, monocrotaline.

  Lafranconi WM, Ohkuma S, Huxtable RJ. Lafranconi WM, et al. Toxicon. 1985;23(6):983-92. doi: 10.1016/0041-0101(85)90391-5. Toxicon. 1985. PMID: 3938082
• Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite.

  Roth RA, Reindel JF. Roth RA, et al. Adv Exp Med Biol. 1991;283:477-87. doi: 10.1007/978-1-4684-5877-0_64. Adv Exp Med Biol. 1991. PMID: 1906225 Review.
• Activation and pulmonary toxicity of pyrrolizidine alkaloids.

  Huxtable RJ. Huxtable RJ. Pharmacol Ther. 1990;47(3):371-89. doi: 10.1016/0163-7258(90)90063-8. Pharmacol Ther. 1990. PMID: 2290854 Review.